AU2022286467A1 - SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES - Google Patents

SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES Download PDF

Info

Publication number
AU2022286467A1
AU2022286467A1 AU2022286467A AU2022286467A AU2022286467A1 AU 2022286467 A1 AU2022286467 A1 AU 2022286467A1 AU 2022286467 A AU2022286467 A AU 2022286467A AU 2022286467 A AU2022286467 A AU 2022286467A AU 2022286467 A1 AU2022286467 A1 AU 2022286467A1
Authority
AU
Australia
Prior art keywords
alkyl
het
independently selected
group
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022286467A
Other languages
English (en)
Inventor
Wei Cai
Xuedong Dai
Nicolas Freddy Jacques Bruno DARVILLE
Samuël Dominique DEMIN
Xiangjun DENG
Natalia Nikolaevna DYUBANKOVA
James Patrick EDWARDS
Fabian HULPIA
Matthieu Dominique JOUFFROY
Susan LEPRI
Ming Li
Chao Liang
Alicia Tee Fuay Ng
Vineet PANDE
Olivier Alexis Georges Querolle
Wim Bert Griet Schepens
Zhen Sun
Johannes Wilhelmus J. Thuring
Zhigao Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2022286467A1 publication Critical patent/AU2022286467A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2022286467A 2021-06-01 2022-05-30 SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES Pending AU2022286467A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021097679 2021-06-01
CNPCT/CN2021/097679 2021-06-01
CNPCT/CN2022/085680 2022-04-08
CN2022085680 2022-04-08
PCT/CN2022/095901 WO2022253167A1 (en) 2021-06-01 2022-05-30 SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
AU2022286467A1 true AU2022286467A1 (en) 2024-01-25

Family

ID=82016507

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022286467A Pending AU2022286467A1 (en) 2021-06-01 2022-05-30 SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES

Country Status (19)

Country Link
US (1) US20230250096A1 (https=)
EP (1) EP4347588A1 (https=)
JP (1) JP2024521879A (https=)
KR (1) KR20240016324A (https=)
CN (1) CN117396476A (https=)
AR (1) AR126011A1 (https=)
AU (1) AU2022286467A1 (https=)
CA (1) CA3218479A1 (https=)
CL (1) CL2023003531A1 (https=)
CO (1) CO2023016217A2 (https=)
CR (1) CR20230605A (https=)
DO (1) DOP2023000250A (https=)
EC (1) ECSP23095641A (https=)
IL (1) IL308862A (https=)
MX (1) MX2023014347A (https=)
PE (1) PE20242359A1 (https=)
TW (1) TW202313606A (https=)
UY (1) UY39795A (https=)
WO (1) WO2022253167A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
US20250197392A1 (en) 2022-04-08 2025-06-19 Janssen Pharmaceutica Nv Crystalline forms of an inhibitor of the menin/mll interaction
EP4626426A1 (en) * 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
WO2024114666A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
AR132185A1 (es) * 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
WO2025119184A1 (zh) * 2023-12-04 2025-06-12 首药控股(北京)股份有限公司 取代的多环化合物
WO2026062248A1 (en) * 2024-09-20 2026-03-26 Acerta Pharma B.V. Solid-state forms of ((s)-2-(3-(1-(5,5-dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1h-pyrrolo[2,3-c]-pyridin-1-yl)-5-fluoro-n,n-diisopropylbenzamide salts

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102984941B (zh) 2009-09-04 2016-08-17 密执安大学评议会 用于治疗白血病的组合物和方法
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
IN2014DN01883A (https=) 2011-09-14 2015-05-15 Proximagen Ltd
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
US10869868B2 (en) 2016-01-26 2020-12-22 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2017214367A1 (en) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
AU2017326006B2 (en) * 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
JP7618567B2 (ja) 2019-09-27 2025-01-21 住友ファーマ株式会社 架橋型光学活性２級アミン誘導体
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物

Also Published As

Publication number Publication date
DOP2023000250A (es) 2024-04-30
ECSP23095641A (es) 2024-01-31
AR126011A1 (es) 2023-08-30
PE20242359A1 (es) 2024-12-16
IL308862A (en) 2024-01-01
CO2023016217A2 (es) 2023-12-11
CN117396476A (zh) 2024-01-12
EP4347588A1 (en) 2024-04-10
TW202313606A (zh) 2023-04-01
CA3218479A1 (en) 2022-12-08
WO2022253167A1 (en) 2022-12-08
UY39795A (es) 2022-11-30
CL2023003531A1 (es) 2024-06-14
JP2024521879A (ja) 2024-06-04
MX2023014347A (es) 2023-12-13
US20230250096A1 (en) 2023-08-10
WO2022253167A8 (en) 2023-03-09
CR20230605A (es) 2024-05-24
KR20240016324A (ko) 2024-02-06

Similar Documents

Publication Publication Date Title
WO2022253167A1 (en) SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES
CN110938076B (zh) 作为tlr7激动剂的吡咯并嘧啶化合物
WO2021121327A1 (en) Substituted straight chain spiro derivatives
AU2022272692A1 (en) Substituted spiro derivatives
AU2022275192A1 (en) Substituted spiro derivatives
WO2023193790A1 (en) Crystalline forms of an inhibitor of the menin/mll interaction
WO2024114664A1 (en) Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
WO2024114658A1 (en) Substituted 1-phenyl-3, 4-dihydropyrido [3, 4-d] pyrimidin-2-one derivatives
WO2024114666A1 (en) Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
WO2024114662A1 (en) Cyclobutyl substituted bicyclic compounds
EP4347600A1 (en) Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
WO2022129333A1 (en) Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1